original ) (raw )Osteoporosis and polymorphisms of osteoprotegerin gene in postmenopausal women – a pilot study
Simeon Grazio
Reumatologia/Rheumatology, 2016
View PDFchevron_right
Investigating the role of osteoprotegerin gene polymorphic variants in osteoporosis
Rita Khusainova
Russian Open Medical Journal, 2021
View PDFchevron_right
Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
Muhammad Saddique shahzad
Frontiers in Pharmacology, 2022
View PDFchevron_right
Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios
Jes Lauritzen
Journal of Bone and Mineral Metabolism, 2004
View PDFchevron_right
Omentin Polymorphism and its Relations to Bone Mineral Density in Women
Joanna Bartkowiak-Wieczorek
Archives of Medical Research, 2015
View PDFchevron_right
Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis
Yoshio Makita
Journal of Human Genetics, 2002
View PDFchevron_right
Efficacy and Safety of Oral Weekly Ibandronate in the Treatment of Postmenopausal Osteoporosis
Katie WILSON
View PDFchevron_right
Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: Orpheum study
Aleksandar Lesic
Srpski arhiv za celokupno lekarstvo, 2011
View PDFchevron_right
Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures
Natàlia García-giralt
Osteoporosis International, 2010
View PDFchevron_right
VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population
Elisabetta Mamolini
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017
View PDFchevron_right
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial
Gaetano Lombardi
Osteoporosis International, 2005
View PDFchevron_right
Association between androgen receptor gene polymorphism and bone density in older women using hormone replacement therapy
Fabien Tigoulet
Maturitas, 2006
View PDFchevron_right
Polymorphisms of OPG and their relation to the mineral density of bones in pre- and postmenopausal women
Joanna Bartkowiak-Wieczorek
International Immunopharmacology, 2015
View PDFchevron_right
Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy
Jacqueline Center
2008
View PDFchevron_right
Gene polymorphisms and osteoporotic fractures: A study in postmenopausal French women
Jean Testa
Joint Bone Spine, 2009
View PDFchevron_right
Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report
Mario Salazar-paramo
Journal of Immunology Research, 2015
View PDFchevron_right
Ibandronate: The Evolution of a Once-a-Month Oral Therapy for Postmenopausal Osteoporosis
David Dempster
Journal of Clinical Densitometry, 2006
View PDFchevron_right
Sequence Variations in the Osteoprotegerin Gene Promoter in Patients with Postmenopausal Osteoporosis
Petra Hudler
View PDFchevron_right
No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women
Amanda Devine
Bone, 2007
View PDFchevron_right
Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs
Jose Luis Hernandez
Pharmaceutics
View PDFchevron_right
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
L. Rowell
Annals of the Rheumatic Diseases, 2006
View PDFchevron_right
Genetic Markers, Bone Mineral Density, and Serum Osteocalcin Levels
Bruce Hollis
Journal of Bone and Mineral Research, 1999
View PDFchevron_right
Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis
Alan Kivitz
The Journal of Clinical Endocrinology & Metabolism, 2009
View PDFchevron_right
Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1Year Results From the MOBILE Study
Paul Miller
2005
View PDFchevron_right
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Arne Hoiseth
Journal of Bone and Mineral Research, 2004
View PDFchevron_right
ASSOCIATION BETWEEN VITAMIN D RECEPTOR GENE POLYMORPHISMS AND OSTEOPOROSIS IN POST MENOPAUSAL WOMEN ATTENDING ZAGAZIG UNIVERSITY HOSPITALS
IJAR Indexing
View PDFchevron_right
Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density
Christopher Vidal
Journal of Molecular Endocrinology, 2011
View PDFchevron_right
Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women
In-kyu Lee
Calcified Tissue International, 2009
View PDFchevron_right
Polymorphisms within RANKL and Osteoprotegerin Genes in Low Bone Mass among Postmenopausal Indonesian Women
Angela Tulaar
Turkish Journal of Osteoporosis
View PDFchevron_right